Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre study.
Vivian D de Jong, Marco Alings, Radan Bruha...
https://pubmed.ncbi.nlm.nih.gov/40447415/Actively Recruiting
Led by Julius Clinical · Updated on 2024-08-01
10000
Participants Needed
13
Research Sites
N/A
Total Duration
Researchers are investigating metabolic dysfunction-associated steatotic liver disease MASLD and its progressive form metabolic dysfunction-associated steatohepatitis MASH in patients who are at high risk due to conditions like type 2 diabetes, metabolic syndrome, obesity, or arterial hypertension. The study aims to implement a patient care pathway across primary care centers in 10 European countries to identify those with MASLD and MASH, while raising awareness among healthcare providers. This observational research will help understand the prevalence and progression of these liver conditions through non-invasive testing and biomarker analysis. The study will screen 10,000 high-risk patients using at least two non-invasive tests, including FIB-4 and FibroScan, to detect liver steatosis, fibrosis, and at-risk MASH. Additional tests and analyses, such as blood samples and liver biopsies, will be collected for genomic, proteomic, metabolomic, lipidomic, and fluxomic studies to better understand disease mechanisms and identify markers for early detection. The study also compares the predictive value of different tests and investigates variations between participating countries. Participants will undergo initial screening and testing at baseline, with some receiving a second FibroScan at 14 weeks and a subset undergoing liver biopsy at 16 or 30 weeks. Blood samples and patient-reported outcomes on diet and lifestyle will be gathered throughout the study. A follow-up period of five years will monitor disease progression and help identify prognostic factors and biomarkers. The primary measurements include prevalence of liver conditions estimated by FibroScan and FAST score, with long-term observation of changes in liver health and associated complications.
CONDITIONS
Global Research Initiative for Patients Screening on MASH
D
de Jong
W
Wijkhuis
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Julius Clinical
Lead Sponsor
UMC Utrecht
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline and up to 30 weeks for some assessments
Participants undergo non-invasive tests and sample collection to assess liver health and identify the presence of MASLD, liver fibrosis, and (at-risk) MASH.
1 to 2 visits depending on tests and biopsy requirement
Duration - 5 years
Participants are followed for 5 years to monitor the natural history of their liver condition and collect ongoing patient-reported outcomes and biomarker data.
Visits at 3 years and 5 years follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Vivian D de Jong, Marco Alings, Radan Bruha...
https://pubmed.ncbi.nlm.nih.gov/40447415/Julius Clinical
Lead Sponsor
UMC Utrecht
Collaborating Sponsor